GLG News by Lipitor Prescribers for Hypercholesterolemia (US)
-
Charles GlueckDirector of Cholesterol CenterJewish Hospital
Study: Lab test can prevent severe blood clots in testosterone patients
September 30, 2011
A recent study finds that a blood test can prevent disastrous blood clots in men receiving testosterone therapy.
-
Ronald InnerfieldVice President of Clinical AffairsEvidence Based Medicine, Inc.
September 30, 2009
Controls to blood sugar 'cuts stroke risk' | www.barchester.com
There have been many epidemiologic studies showing a very tight correlation between baseline A1c and cardiovascular mortalityDespite this, five major randomized prospective studies have failed to show any macrovascular benefit for tighter glucose controlThe logical conclusion is that glucose is, therefore, a marker for increased mortality but not a modifiable risk factor thereofThis is why FDA has mandated cardiovascular safety for new antidiabetic agentsData dredging persists, however
-
Howard WeintraubClinical DirectorNEW YORK UNIVERSITY (INC)
Another piece of good news for a very good drug
November 8, 2007
Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level of BNP. This has not been as successful in patients without myocardial ischemia, but in those with ischemia the shortness of breath and associated chest discomfort has been helped in many. Including the most recent patient with a severe ischemic cardiomyopathy who has responded very very well with a significant increase in his functional capacity. Hopefully this news along with the safety from MERLIN and the A1C data and reduction in arrhythmias in that study will awaken docs to the benefits of Ranexa.
-
Howard WeintraubClinical DirectorNEW YORK UNIVERSITY (INC)
November 8, 2007
Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.
-
Howard WeintraubClinical DirectorNEW YORK UNIVERSITY (INC)
June 15, 2007
FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in the near and mid-term future. This does not bode well for Sanofi, who will not have to regroup and pray for success with son of Amiodarone.
-
Howard WeintraubClinical DirectorNEW YORK UNIVERSITY (INC)
June 15, 2007
FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone mess (with Baychol and Vioxx undertones). This is going to create a real challenge for Sanofi and make them pray for succes with the "son of amiodarone".
-
Charles GlueckDirector of Cholesterol CenterJewish Hospital
CETP INHIBITORS- A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC
March 6, 2007
CETP INHIBITORS: A PROBABLE CLASS ACTION EFFECT TO BE PROATHEROGENIC | mediaroom.pfizer.com
By reducing fractional catabolic rate and by producing a large, cholesterol rich HDL molecule which could not easily be cleared by hepatic HDL receptors, our research group in Cincinnati thought from the beginning that the CETP inhibitors AS A CLASS would fail, and might even be proatherogenic. Regrettably, with torcetrapib this sequence of events seemed to occur. Our concern is that this is a class effect and that CETP inhibitors are not a fruitful area for further drug development.
-
Hossein ArdehaliAssociate ProfessorNorthwestern University, Feinberg School of Medicine
New studies suggest DES may improve outcome in the setting of AMI
September 19, 2006
NEJM Articles on DES in MI | content.nejm.org
The studies reported in the recent issues of NEJM are significant in that they provide evidence that DES in the setting of AMI with ST elevation may improve outcome. Taxel-eluting stents showed nonsignificant improvement in adverse cardiac events, but sirolimus-eluting stents showed a significant reduction in target vessel revascularization
-
Hossein ArdehaliAssociate ProfessorNorthwestern University, Feinberg School of Medicine
Generic clopidogrel should not alter its use
August 18, 2006
Mixed thoughts on how generic clopidogrel might impact patients, providers | www.theheart.org
There are clear indications to use clopidogrel
Clopidogrel should not be used in every patient with coronary artery disease
Page : 11 to 9 of 9
Leading institutions connect with members of the Healthcare councils through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.